Search results
3 dni temu · ATLANTA--(BUSINESS WIRE)-- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD ...
4 dni temu · ATLANTA - Alzamend Neuro, Inc. (NASDAQ:ALZN), firma biofarmaceutyczna w fazie klinicznej, ogłosiła, że ponownie spełnia wymogi Nasdaq dotyczące kapitału własnego akcjonariuszy. Spółka, która pracuje nad terapiami na chorobę Alzheimera i inne zaburzenia psychiczne, otrzymała 14.10.2024 r. oficjalne powiadomienie od Nasdaq Stock ...
3 dni temu · Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. ... 3 Biotechs Seek Over $700M in Renewed IPO Rush. September 13, 2024 · 2 min read · Annalee Armstrong.
4 dni temu · Alzamend Neuro Regains Compliance with Nasdaq Listing Standards. ATLANTA, GA, October 15, 2024 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today ...
2 dni temu · On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary ...
4 dni temu · Get a real-time Alzamend Neuro, Inc. (ALZN) stock price quote with breaking news, financials, statistics, charts and more.
10 paź 2024 · We initiated the Phase I/IIA clinical trial in March 2023. Alzamend Neuro® , Inc., (“Alzamend® ”), a Delaware corporation with its headquarters in Atlanta, Georgia, is a clinical-stage, biopharmaceutical company.
